生命科学资讯

After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate

Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic push

Nektar posts one-year eczema success; Pfizer ends malnutrition trial

The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more

Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study

Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan

Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1

Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges

Pfizer dips on new data for obesity drug acquired in $10B deal

Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b

Pfizer takes $4.4B charge related to cancer drug in fourth-quarter earnings

Pfizer’s Metsera-originated monthly GLP-1 cuts weight by 10.5% at six months

Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ

Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs

Pfizer to depart GSK's ViiV as Shionogi doubles its stake

JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year

At FDA's request, Pfizer helps ease shortage of potential autism drug

Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential

French biotech Enodia gets €20.7M aided by Pfizer for protein degrader work

Updated: Pfizer discloses patient death in Hympavzi hemophilia trial